Serious adverse events within 6 monthsb · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Tixagevimab/cilgavimab showed no clear difference in serious adverse events within 6 monthsb compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality up to 30 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
Summary of findings table ‐ Corticosteroids plus standard care probably leads to lower all‐cause mortality up to 30 days compared with standard care (plus/minus placebo) (moderate certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ Corticosteroids plus standard care changes all‐cause mortality up to 120 days compared with standard care (plus/minus placebo) (very low certainty).
1 finding from 1 review
Clinical improvement: discharged alive ( · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
Summary of findings table ‐ Corticosteroids plus standard care may leads to higher clinical improvement: discharged alive ( compared with standard care (plus/minus placebo) (low certainty).
1 finding from 1 review
Clinical worsening: new need for invasive mechanical ventilation or death · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
Summary of findings table ‐ Corticosteroids plus standard care showed no clear difference in clinical worsening: new need for invasive mechanical ventilation or… compared with standard care (plus/minus placebo) (low certainty).
1 finding from 1 review
Serious adverse events ( · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
1 finding from 1 review
Adverse events: all grades · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
1 finding from 1 review
Hospital‐acquired infections ( · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
1 finding from 1 review
Invasive fungal infection · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
1 finding from 1 review
OutcomesTime frame of absolute effects · hospitalised people with confirmed SARS‐CoV‐2 infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (up to day 28) · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
All‐cause mortality (up to day 60) · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
Improvement in clinical status: discharged alive or hospitalised, but no longer requiring ongoing medical care (up to day 28) · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
Clinical worsening: new need for invasive mechanical ventilation or death · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
Adverse events: all grades · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
Serious adverse events · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
Secondary infection · hospitalised people with confirmed SARS‐CoV‐2 infection
1 finding from 1 review
All‐cause mortality (at day 28) · symptomatic people with COVID‐19
Fluvoxamine plus standard care showed no clear difference in all‐cause mortality (at day 28) compared with placebo plus standard care (low certainty).
1 finding from 1 review
All‐cause admission to hospital or death (before hospital admission) · symptomatic people with COVID‐19
Fluvoxamine plus standard care showed no clear difference in all‐cause admission to hospital or death (before hospital admission) compared with placebo plus standard care (low certainty).
1 finding from 1 review
Resolution of symptoms · symptomatic people with COVID‐19
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found